Hyperion signs deal with Ucyclyd to acquire adjunctive therapy rights
The terms of the deal have not been disclosed. Hyperion also entered into an amended and restated collaboration with Ucyclyd according to which Hyperion retains an option to
Evogene and ELEO have entered a scientific collaboration aimed at discovering and developing new oral small-molecule inhibitors targeting the Proprotein convertase subtilisin/kexin type 9 (PCSK9) pathway for hyperlipidemia and cardiovascular diseases.
The company specializes in the process, development and manufacture of active pharmaceutical ingredients, nutraceuticals, natural extracts, enzymes and specialty polymers. Bio-gen Extracts marketing director Saif Mehkri told Pharmabiz
EVMPD compliance solution has been fully tested to compliantly generate valid, syntactically-correct XML data. Centrality software allows Marketing Authorisation Holders (MAHs) to easily convert existing medicinal product information